The stock may react positively to the financing and Phase 2a data, but traders should be cautious of the non-cash nature of the net income and the ongoing FDA clinical hold for the TXM program.
Price Chart
Executive Summary
Traws Pharma reported a net income of $9.2 million for FY2025, a significant improvement from a $166.5 million loss the prior year, driven by a $26.6 million gain from warrant liability revaluation and reduced R&D expenses. The company also announced a $60 million private financing and positive Phase 2a data for its ratutrelvir program, showing faster symptom resolution in PAXLOVID-ineligible patients.
Key Financial Metrics
Key Facts
- Net income of $9.2 million for FY2025 vs. a $166.5 million loss in FY2024, primarily due to a $26.6 million change in fair value of warrant liability.
- Completed a $60 million private financing ($10 million upfront) to fund operations into Q1 2027.
- Positive Phase 2a topline data for ratutrelvir showed faster symptom resolution in PAXLOVID-ineligible patients and favorable safety.
- Cash and cash equivalents were $3.8 million as of December 31, 2025, down from $21.3 million the prior year.
- R&D expenses decreased to $12.1 million from $12.8 million.
Financial Impact
Net income of $9.2 million driven by non-cash $26.6 million gain; $10 million upfront from $60 million financing.
Risk Factors
- FDA clinical hold on the TXM program due to toxicology data concerns.
- Reliance on non-cash gains to achieve net income, with cash burn reducing reserves from $21.3 million to $3.8 million.
- Dilution from the $60 million financing with milestone-based and three-year warrants.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-043781 |
| Document: tm2611843d2_8k.htm | 0001104659-26-043781 |
| Document: 0001104659-26-043781-index-headers.html | 0001104659-26-043781 |
| Document: 0001104659-26-043781-index.html | 0001104659-26-043781 |
| Document: 0001104659-26-043781.txt | 0001104659-26-043781 |
| 8-K Data (Synthetic) | 0001104659-26-043781 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | S-1 | $0.3500 | awaiting T+20 | — | $0.3400 (+2.86%) |
Oct 23, 2026 3d ago | 8-K | $0.3510 | awaiting T+20 | — | $0.3400 (+3.13%) |
Oct 20, 2026 6d ago | DEFA14A | $0.3760 | awaiting T+20 | — | $0.3400 (−9.57%) |
Oct 20, 2026 6d ago | DEF 14A | $0.3760 | awaiting T+20 | — | $0.3400 (+9.57%) |
Aug 14, 2026 10w ago | Press Release | $0.5400 $0.5200 | ▲ +3.70% | ▲ +2.18% | $0.3400 (+37.04%) |
Jul 10, 2026 15w ago | 8-K | $0.6849 $0.5400 | ▲ +21.16% | ▲ +24.34% | $0.3400 (+50.36%) |
Jul 10, 2026 15w ago | 424B5 | $0.6849 $0.5400 | ▲ +21.16% | ▲ +24.34% | $0.3400 (+50.36%) |
Jul 10, 2026 15w ago | EFFECT | $0.7600 $0.5320 | ▲ +30.00% | ▲ +32.43% | $0.3400 (+55.26%) |
Jul 9, 2026 15w ago | 8-K | $0.7600 $0.5320 | ▼ −30.00% | ▼ −32.43% | $0.3400 (−55.26%) |
Jul 1, 2026 16w ago | S-3 | $0.7677 $0.4411 | ▼ −42.54% | ▼ −42.13% | $0.3400 (−55.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers